Original by:
Cataloguing table of contents
BVSc, BScAgr, MANZCVS (SAIM), DACVIM
The primary treatment for acute insulinitis in dogs is support for sexual care, including liquid therapy and nutrition management.
Acute pancreas is related to abdominal pain. Depending on its severity, it may also be associated with mild, non-specific, self-restrictive clinical symptoms, or with cardiovascular shock, amphibious internal coagulation (DIC) or multi-organ failure.
Given that canine acute insulin outbreak is a complex, self-perpetuating and self-absorption process, it is difficult to predict whether the patient ' s condition is mild or rapid. Persons with subclinic and mild pancreas can display mild, non-specific clinical symptoms, such as sleeping addiction and intermittent anorexia, who are frequently misdiagnosed. When it is suspected that they are suffering from pancreasitis, these patients are usually treated in hospitals for anti-opaed drugs (e.g., Maro Pitan), subcutaneous injections and low fat diets. The more serious cases of pancreas require active support and hospitalization, which includes pain relief, nutrition management, anti-opaque medication, gastrointestinal acid inhibition and the correction of fluids, electrolyte and acidic abnormalities.
This paper discusses the main aspects of the treatment of acute pancreas disease in dogs. The recommendations are based on published evidence of support (if such evidence exists); however, when objective data are not available to support the current recommendations, they are based on published standard care guidelines, impeccable evidence and clinical experience. The pain of pancreas.
A dog suffering from pancreas can suffer from local and internal pain. The pain rating system is usually used to assess the severity of pain and to determine pain relief programmes; however, analgesics have not been assessed on dogs suffering from acute pancreas.
In the author ' s institution, the pain level is determined by the degree of pain according to the degree of pain, which is determined by the system of behavioural and physical pain scoring, using a multi-dimensional, individualized approach to the pain. The first analgesics are opioids (full or partial μ agonists). NMDA (N-My-D-Zytoxin) stressants (e.g. ketamine) and/or local anaesthesia (e.g. Lidocaine) can then be added as auxiliary drugs for intravenous constant infusion, depending on the severity of the pain.
ketamine is the preferred option when animals continue to experience subjective or seemingly uncomfortable use of opioids. Symptoms of continued pain may include sound / cry, inability to respond or interact with people, and vigilance, sound or evasion during abdominal contact. The role of ketamine in reducing central sensitivity may help to reduce the perception of harm to internal organs and internal peritoneal parts.
For animals with persistent symptoms of incurable behaviour and physical pain, Lidocaine can be added to drug treatment (Table 1). Not only does the Lidocaine have a painful effect, but it has also been shown to improve gastrointestinal functions and to be resistant to inflammation. When a patient eats, he or she is usually converted to oral drugs, such as tramadol and/or gabaptine (table 1). Since most dogs suffering from severe acute pancreas disease suffer from inadequate blood capacity and dehydration, the use of accelerants (NSAID) is not recommended.
Nutrition management of canine pancreas
Historically, there has been a preference for “suspension” of pancreas by stopping intestine nutrition during acute pancreas outbreaks, in order to avoid stimulating the excretion of pancreas and increasing the risk of premature enzymes activation. There was little evidence to support such an approach and several studies questioned it. There is growing evidence that early intestine nutrition improves clinical outcomes for people with systemic diseases. In particular, early intestine nutrition has been shown to reduce enteric infarction and inflammation, to stimulate regenerative and mucous membrane blood flow, to reduce the decomposition of protein metabolism and to prevent protein energy malnutrition. A recent retrospective study of 34 dogs suffering only from acute pancreasitis concluded that early intestine nutrition (i.e. within 48 hours of hospitalization) has a positive impact on the restoration of voluntary food intake, which is related to intolerant gastrointestinal tracts and should be considered part of medical management.
Forced anorexia can be counterproductive to overall gastrointestinal health by avoiding intestine nutrients associated with increased gastrointestinal penetration, bacterial or internal toxin susceptibility and immunosuppression. Increased metabolic demand associated with pancreas per se, protein decomposition metabolism and bacterial alternation can lead to overall inflammation response syndrome (SIRS).
In the author ' s hospital, the nasal and gastric tubes are usually used for the treatment of acute pancreas. The placement of feed pipes is relatively cheap and generally resistant. The use of syringes for feeding is not recommended because it does not actually provide the full nutritional demand and is at risk of anorexia and inhalation.
Ideally, resident dogs should feed their estimated silent energy demand (RER) on the basis of 70 x (weight, kg) = RER (kcal/day) or [30 x (weight, kg)] + 70 = RER (kcal/day). The first formula is a more precise one, used in the author's body for 25 kg of dog, while the second formula is an approximation of RER for 5 to 25 kg dog. The provision of at least part of RER in this way may be beneficial for maintaining the absorption surface area of the intestinal tract for patients who are unable to withstand full ER as intestinal nutrients.
There is currently a liquid intestine diet specifically designed for veterinarians (table 2). Human intestine diets can be used for short-term feeding, but their fat, protein and essential nutrient content are low and not suitable for long-term use. It's an anti-powder pill.
Obsessive appetites associated with vomiting and nausea are common among acute pancreas patients, and anti-pussic drugs are commonly used to treat these symptoms. These symptoms may be guided by circulatory accelerants in the centre and by enteric infarction, perimenitis and pancreas damage in the outer week. Several types of anti-smoking drugs are often used for treatment and are considered to be effective and useful, although few have been rigorously tested; table 1 lists 11 common options.
Malopitan is a NK1 receptor. Antigen is a front-line vomiting drug that acts both at the centre centre (i.e. at the chemical sensory trigger and at the vomiting centre) and outside (the gastrointestinal tract). The study found that Maro Pitan was better at treating irritating vomiting than methylenedioxychloropamine. Studies have shown that, in addition to vomiting, Maropitan can suppress inflammation by blocking NK1 receptors in pancreas. Other anti-inflammatory anti-optants, such as serotonin stressants (e.g. Ontan Sijon), can be added as needed to improve nausea and control vomiting.
In the author ' s institution, Maropitan is the preferred anti-pump medicine. For dogs that are resistant to the drug, methylenedioxychloropamine (1 to 2 mg/kg, once every 24 hours, with a constant rate of loss) or Ondashjong (0.1 to 1.0 mg/kg, every 6 small to every 12 hours) can be used as additional support therapy.
The Veterinary Examination (with downloads) required a full set of videos + documentation (with small stoves & Zeave video web lessons + mind map + four colour notes + summary of mouths + reality + practice)
Proton pump inhibitors (e.g., Omera, Pythrazine) and groupamine type 2 (H2) Receptor stressants (e.g., Famotidesine, Renedidides) are useful assistive drugs that reduce the risk of stomach or intestine ulcer or bronchitis (table 1).
During the treatment of acute pancreasitis, reduction of stomach acidity is often recommended, although there is no evidence that reduction of stomach acidity can lead to insulin Endocrine stimulation reduces or improves the prognosis of dogs suffering from acute pancreas. However, clinical evidence of stomach ulcer (basket or black defecation) or oesophagus (repeated gas, reverse) indicates a need to suppress stomach acid.
When used twice a day, proton pump inhibitors are better than H2 resistants in terms of increasing pH values in the stomach. The short-term combination of H2 stressants and proton pump inhibitors will not produce better results than the use of any single drug type. IVS treatment
Pancreas micro-circle disorders play an important role in the mechanisms for acute pancreas and in the transition from acute self-restricted pancreas to severe fatal pancreas. Pancreas microcyclic disorders may be affected by a number of factors, including insufficient blood capacity, dehydration, increased permeability of hairy blood vessels and microbreeding.
The rationale for intravenous fluid treatment is to supplement blood capacity, thereby increasing the flow of pancreas, which, according to some animal studies, improves both pancreas circulation and survival. However, liquid recovery alone cannot fully restore pancreas blood flow and oxygen consumption. Little information is available on the optimal initial liquid selection; however, impermeable liquids (e.g. lactation lings, 0.9% sodium chloride) are appropriate. The liquid plan shall include estimated fluid losses, any continuing loss (i.e. vomiting, diarrhoea) and ongoing maintenance needs. The electrolyte should be monitored and supplemented accordingly.
For dogs suffering from severe acute pancreasitis, crystal therapy alone may not be sufficient. The adhesive medicine has been studied in persons suffering from pancreasitis, and the results have improved compared to crystal recovery. At present, the role of adhesive solutions in the management of pancreas among veterinarians is controversial. Several human studies and a recent veterinary study have shown that the use of glue increases the risk of renal dysfunction, coagulation / slab dysfunction and death. More forward-looking longitudinal research is needed in the field of veterinary medicine to investigate the increased risk (e.g., acute kidney damage) associated with the use of glue by persons at risk.
Other blood transfusions for canine pancreas.
Information on the use of plasma in acute pancreas is also scarce. The so-called benefits of plasma transfusions include the correction of low-protein haematosis and the supplementation of circulatory antiproteus (e.g. alpha giant protein, anti-insulin), coagulation and anti-inflammatory factors. A retrospective study of plasma use in 77-year-old dogs with acute pancreas only. The study concluded that fresh frozen plasma was not a good drug and that, until further evidence was available, plasma transfusions should be used only for recorded cases of pancreasitis. There is a lack of research into the use of other blood products by these patients. Sugar cortex hormones
Historically, sugar cortex hormones have been avoided for dogs suffering from acute pancreas. Sugar cortex hormones are no longer considered to cause pancreasitis in dogs; however, there is currently no consensus on the use of sugar cortex hormones or optimal time/dose for pancreas patients.
Sugar cortex hormones can almost offset all inflammation pathways. In the case of pancreas, they have been shown to enhance cell decay and increase the production of related proteins for pancreas, thereby protecting pancreas. A recent clinical study has shown that C-reacting protein concentrations in dogs treated daily by 1 mg/kg Pennion have declined even more, with shorter clinical improvements, shorter hospitalizations and higher survival rates. The findings of these studies should be viewed with caution and maximum use should be made of other aspects of active medical management of pancreas before sugar cortex hormone treatment is administered. Further objective clinical trials are required to validate the results of the latest studies. Antibiotics
Antibiotic treatment for acute pancreas is not recommended, as pancreas is considered to be an sterile inflammation process, often accompanied by fever and increased white cells. Indicators of the use of antibiotics include lack of response to active support treatment, back-to-back infections/suppressions associated with pancreas necrosis, or suspicion of black defecation and gout blood caused by bacterial movement in the intestines. In case of indications, consideration should be given to the use of wide intestinal antibiotics effective for gastrointestinal pathogens (e.g. Amosilin – Kravi acid). Surgery.
There may be a need for surgical treatment of acute pancreas severe when there is evidence of persistent bold obstruction, ineffective positive medical treatment, persistent long-end organ complications or pancreas or infection. The purpose of the operation is to relieve persistent choreography of the liver and to remove disease/inactivity or abscess tissues by means of cholesterol artery or choreography. The survival rate for dogs requiring pancreas sepsis ranges from 0% to 56%; for dogs undergoing ecstasy due to ecstasy, it ranges from 50% to 80.8%. Physitis and sepsis are the most common post-operative complications. Pregnosis of pancreas.
Assessing the severity of acute canine pancreas is challenging, and several rating systems have been proposed to assess the severity and prognosis of the disease. Unfortunately, these rating systems have not yet been recognized as useful on a global scale. Indicators for serious diseases and adverse prognosis include SIRS, shock, DIC, reduction of slabs, extended time of coagulation, renal nitrogen haemorrhage, less or no urine, metabolic acid poisoning, yellow sluice, elevated aminoase, high potassium haemaemia, low calcemia, low sodium haemoemia, low/high blood sugar, excessive hypothermia, serosuctic fatase > 1000 μg/L (through Spec cPL) tests, continuous increase of C-reacting protein and urine pancreas activity: increased acetic anhydride ratio. Permanent follow-up visits
Once the dogs are well fed and clinically stable (i.e. no signs of sleeping addiction, vomiting, abating appetite), they can be discharged. In the author ' s hospital, oral painkillers (e.g. tramadol, gabaptine) are opened for patients who continue to suffer from mild abdominal discomfort upon discharge.
Dietary adjustment is the most important component in the long-term treatment of acute pancreas. Sudden changes in high-fat diets, food types and compositions, and leftovers from garbage or table meals should be avoided. It is generally accepted that the fat content in the diet should be less than 30 g/1,000 kcal. HB dogs should feed 14 grams of fat per 1000 calories to reduce seroglycerine trimer and cholesterol.
The known complications of acute canine pancreas include ecstasy, diabetes and diabetic ketone acidism, and acute sepsis (i.e. pancreas sepsis or pseudocystema). The recurrence or recurrence of acute pancreas can lead to the development of chronic pancreas, insufficiency of pancreas (EPI) or diabetes. Out-of-hepatic cholesterol blockage is a partial complication of acute pancreas, usually manifested in yellow flu within 3 to 7 days of the outbreak. According to the experience of authors and others, ecstasy and acute screeching of the ecstasy in the liver may recede spontaneously over time. If necessary, acute flow of fluids has been described previously. This is a relatively safe operation with few complications.
Diabetes is a common combination of pancreas, and beta cells can suffer “bystander damage” as a result of non-specific inflammation or self-immunisation processes. However, a potential problem remains: “Does pancreas cause diabetes or diabetes causes pancreas?” The exact causal link has not yet been clarified, and the two diseases may increase each other.
Dogs with diabetes mellitus or EPI should be treated by injection of insulin, lifestyle advice and dietary management or by adding pancreas formulations to food and supplementing enteric cobaltamine.